Amneal Pharmaceuticals announced the commercial launch of bevacizumab-maly (Alymsys), a biosimilar referencing bevacizumab (Avastin, Genentech), in the United States.
Bevacizumab-maly is a vascular endothelial growth factor inhibitor used in oncology that was developed by mAbxience.
“The launch of Alymsys provides additional access and choice to affordable oncology therapeutics for providers and patients,” said Harsher Singh, the senior vice president of Amneal Biosciences.